The US Food and Drug Administration (FDA) is replacing the term artificial intelligence with “super intelligence” across its official communications, implementing a presidential directive that changes how the federal government describes AI technologies. The decision could also reshape the language used in future federal legislation, although private healthcare companies are not immediately affected.
The terminology switch took effect Monday, according to the FDA announcement reported by RAPS. It covers government correspondence, public announcements, websites, reports and policy materials. However, the agency says existing regulations and previously published guidance will retain their original wording until relevant updates take place.
Trump ordered terminology change
The FDA's decision follows an executive order signed in September by President Donald Trump. The directive instructs executive departments and federal agencies to stop using the established term artificial intelligence in favor of “super intelligence.”
The order argues that the older terminology does not adequately communicate the capabilities and opportunities associated with these technologies. It presents the replacement as a better reflection of their potential and rapid development.
The directive also assigns a legislative task to the Assistant to the President for Science and Technology (APST), the White House official responsible for science and technology advice. Within 60 days of the order, the assistant must submit proposed legislative language establishing a definition for “Super Intelligence.”
That requirement could give the terminology change a longer life beyond government communications, depending on whether lawmakers subsequently adopt the proposed language.
Companies are exempt for now
The order applies to executive branch departments and agencies rather than private-sector organizations. Sydney White, an attorney at Wiley Rein LLP, told Focus that pharmaceutical manufacturers and medical device companies therefore do not have to adopt the replacement terminology.
However, White identified a possible route for the directive to affect businesses in the future: provisions from the executive order could become legislation. If that happens, private organizations might face requirements that do not currently apply to them.
For now, the FDA's change is an administrative terminology decision rather than a new naming requirement for companies developing healthcare products.
Experts question the meaning
Christina Silcox, research director for digital health at the Duke-Margolis Institute for Health Policy, characterized the decision as largely semantic. She told Focus that neither artificial intelligence nor super intelligence has a sufficiently precise definition to eliminate confusion about what particular systems can actually do.
Both expressions cover a broad range of technologies, and their technical meanings do not always align with how people use them in everyday conversation. Replacing one broad label with another therefore does not necessarily make the underlying technology easier to understand.
Silcox also highlighted a more practical concern for healthcare. Applying the super intelligence label broadly to clinical and related healthcare tasks could encourage doctors and patients to place too much confidence in AI-generated results.
“I would consider this more of a semantic change”
— Christina Silcox, Duke-Margolis Institute for Health Policy
She argued that healthcare organizations need effective governance systems that explain the capabilities and limitations of individual tools. Users should know what a particular system is designed to accomplish, the situations in which it is appropriate, and how its outputs should influence decisions.
Existing FDA documents remain
The FDA has clarified that the terminology change will not automatically rewrite its existing regulatory framework. Previously issued guidance, regulations, Federal Register notices and other agency publications will remain unaffected.
There is also an important legal distinction when the agency refers to existing statutes and regulations. If legislation or a regulation contains the words artificial intelligence or AI, the FDA will preserve that wording when quoting or citing the relevant provision.
The agency plans to update public-facing materials through its normal revision and website maintenance processes rather than replacing every existing reference immediately. Documents will receive conforming terminology changes when they undergo their next substantive update.
Why it matters
The FDA's decision introduces a politically directed vocabulary change into one of the world's most influential medical regulatory agencies. But the immediate consequences are narrower than the new terminology might suggest: existing rules remain intact, companies are not required to follow the change, and the technical capabilities of healthcare AI systems are unaffected by their new label.
The more consequential development may come from the White House's planned legislative definition. The APST's proposed language, due within 60 days of the September order, could establish how the federal government formally distinguishes super intelligence from other AI technologies.
For healthcare, the central issue remains whether clinicians and patients understand the specific systems they use. As Silcox's warning suggests, changing the name without clarifying capabilities could make responsible oversight more difficult rather than easier.